APTOSE BIOSCIENCES INC (APTO) Stock Analyst Ratings
USA - NASDAQ:APTO - CA03835T4081 - Common Stock
1.71 USD
-1.44 (-45.71%)
2.16 USD
+0.45 (+26.32%)
ChartMill assigns a Buy % Consensus number of 83% to APTO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 85.85. This target is 4920.47% above the current price.
APTO was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about APTO.
In the previous month the buy percentage consensus was at a similar level.
APTO was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-08-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-12 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-06-12 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-06-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-06-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-05-09 | Oppenheimer | Reiterate | Outperform |
| 2023-05-09 | RBC Capital | Reiterate | Outperform |
| 2023-05-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-27 | Canaccord Genuity | Maintains | Buy |
| 2023-03-24 | RBC Capital | Reiterate | Outperform |
| 2022-11-02 | RBC Capital | Maintains | Outperform |
| 2022-05-10 | RBC Capital | Maintains | Outperform |
| 2021-12-21 | HC Wainwright & Co. | Maintains | Buy |
APTOSE BIOSCIENCES INC / APTO FAQ
What do analysts expect the price target to be for APTOSE BIOSCIENCES INC (APTO)?
8 analysts have analysed APTO and the average price target is 85.85 USD. This implies a price increase of 4920.47% is expected in the next year compared to the current price of 1.71.
What is the consensus rating for APTOSE BIOSCIENCES INC (APTO) stock?
The consensus rating for APTOSE BIOSCIENCES INC (APTO) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for APTO stock?
The number of analysts covering APTOSE BIOSCIENCES INC (APTO) is 8.